Tuesday, July 31, 2012

AIDS 2012

The first time that I remember hearing about HIV/AIDS was the day the principal of my elementary school retired in 1993.  We were at an assembly and the principal was speaking, giving a resignation speech.  I was paying more attention to my feet than anything else but as he finished, I looked up and saw that all of the adults in the room, including my mother, were crying.  I asked her what was wrong and she told me he had AIDS.  It would be a long time before I really understood what this meant.  (correction: my mother informs me she does not remember this happening).

Flash forward: I am a college graduate working in a multidisciplinary clinic caring for HIV positive patients and I have been given the opportunity to attend the International AIDS Society conference in Washington DC.  It is absolutely incredible how far medicine has progressed in less than 10 years.

In remembrance of 1993: there was only one drug available for treatment.  Zidovudine, which was first marketed in 1987, is a nucleoside reverse transcriptase inhibitor or "NRTI".  It is the only anti-retroviral drug currently available in intravenous formulation and is still used in patients today.  However, in light of the most current guidelines, it is shocking to think of using a single medication in treatment of HIV, which mutates rapidly.  Current drug regimens typically include two NRTIs and a third medication from a different medication class.  The first protease inhibitor did not become available until 1995.  In 1993, there were already multiple case reports of drug resistant strains of HIV to the only available drug, zidovudine, developing after the patient had been on the medication for six months or longer.

Aside from the vast medical advances we have made in the treatment of HIV, it is also worth reflecting how global society has changed since the CDC first recognized HIV in 1981 to the day my principal retired in 1993 to today.  In the 1980s, a diagnosis of HIV, a virus well known but not well understood, was a death sentence.  The introduction of antiretrovirals provided hope but fear continued to run deep in 1993 and today.

A week ago at the AIDS 2012 conference Hillary Clinton called for an AIDS free generation, an incredibly bold statement that may in fact be feasible if governments, societies, and health-care professionals continue to fight.  I think that making a distinction between an "HIV free generation" and "AIDS free generation" is important to make at this moment.  Hillary's plan outlined in her speech focused primarily on increasing efforts at prevention of new infection, but separating the idea of an AIDS free generation from that of an HIV free one would indicate that improving the quality of care for our HIV positive patients could prevent AIDS and allow all patients with a positive status the right to a long and healthy life.

AIDS, or Aquired Immune Deficiency Syndrome, occurs when the human immunodeficiency virus has destroyed enough of the immune system that it is no longer able to prevent the patient from contracting infections that healthy individuals would not be subject to.  Preventing AIDS would include:

- Test more people: many patients receive a diagnosis of AIDS along with a HIV diagnosis upon initial presentation.  The CDC recommends that all individuals between 13 and 64 years of age receive at least one HIV test in their lifetime and more frequently if they engage in high risk behavior, ie unprotected anal sex and sharing needles.

- Improve follow up.  Many patients receiving a diagnosis of HIV/AIDS never follow up and therefore are unable to receive treatment which would likely result in the progression of their disease to AIDS.

- Get more patients on treatment: medications are expensive but there are a number of assistance programs available.  From a global perspective, many countries reserve treatment for when patients develop AIDS because limited treatment options in certain countries increase the risk of developing resistance or losing control of the epidemic if resistant strains are widespread.  The type of intervention for improvement would depend on the country.

- Get more patients to an undetectable viral load on treatment: This means that the medication is working and the patient is taking it like they are supposed to.  Unfortunately, HIV hides in certain cells and there is no cure for HIV currently, but having an undetectable viral load allows for the immune system to recover.  In a presentation at the conference, it was estimated that about 50% of HIV positive patients (including those not yet tested) had an undetectable viral load versus about 25% of HIV positive patients in the United States.

I was also fortunate enough to attend a profound session moderated by Laurie Garrett, the author of "The Coming Plague", the book that sparked my interest in epidemiology and public health.  She began with a quote from the World Health Organization:

"The social determinants of health are the conditions in which people are born, grow, live, work and age, including the health system.  These circumstances are shaped by the distribution of money, power and resources at global, national and local levels.  The social determinants of health are mostly responsible for health inequities - the unfair and avoidable differences in health status seen within and between countries."  In other words, how do government, health care structure, social norms and culture influence a person's health?

Also on the panel was Dr. Nono Simelela who ran (runs?) the South Africa AIDS counsel and continues to work closely with the current president.  Ms. Garrett set the stage discussing that in a society where 1/3 of the population is HIV positive, people in the society became fatalistic.  They saw HIV as unavoidable with death at its heels, and as a result, this fatalism contributed to increased unemployment and further reduced morale.

Dr. Simelela responded saying that it truly is an epidemic of depravation.  Aside from looking for funding for HIV programs, South Africa analyzed the gains already made and uses allotted funds to not only move forward, but to ensure that the gains made are not lost.  On striving for an AIDS free generation, she discussed the need to get more people involved.  It will not work if it is only government officials changing laws, everyone will need to be an educator.  Patients may spend a few hours with a health care professional per year if they choose to access the health system, but that does not account for the 5000+ hours spent doing everything else.  HIV is an issue that needs to be discussed from different angles.  If people are not talking about it in terms of helping things progress, then little will be gained by society.

I could go on for pages over what I saw at the conference and what was said in this session, but I will end with a quote from a member of that panel, Michaela Clayton, who works in Namibia:

We don't defend human rights because people have HIV, we defend human rights because people have human rights.



References:
http://www.kff.org/hivaids/timeline/hivtimeline.cfm

Erice A et al.  Primary infection with zidovudine-resistant human immunodeficiency virus type-1.  The New England Journal of Medicine 1993; 328:1163-5.

http://www.who.int/social_determinants/en/

Asch DA et al.  Automated hovering in health care - watching over the 5000 hours.  The New England Journal of Medicine 2012; 367(1):1-3. 

Saturday, June 9, 2012

Statins in Low Risk Patients

Although data supporting the use of statins to reduce cardiovascular risk are extensive, questions remain.  Currently experts in cardiovascular health are in disagreement over the use of statins in low-risk patients, particularly patients with high cholesterol but no other cardiovascular risk factors.

While statin benefits are well established, real-world cohort studies have shown higher risks of complications and side-effects than seen in randomized-controlled trials.  For every 100 otherwise healthy men men who take a statin for five years, one or two myocardial infarctions will be prevented but at least one patient will develop diabetes, and 20% or more will experience significant side effects.  

One side of the argument states that in low-risk patients, clinicians should focus on lifestyle changes such as diet, exercise and smoking cessation.  The use of statins in primary prevention is not a standard of care and the decision to initiate therapy should be based off a careful assessment of risk versus benefit.

Although previous meta-analyses have stressed that there is no mortality benefit with statins for primary prevention, a recent meta-analysis published in The Lancet showed that proportional reduction in major vascular events was as great in low risk patients as in high risk patients.  Despite the author’s conclusion that statins are beneficial in low risk patients, clinicians remain divided over this issue.

References: 
Redberg RF, Katz MH.  Healthy men should not take statins.  Journal of the American Medical Association 2012; 307(14):1491-3.
Mihaylova B, Emberson J, Blackwell L et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: a meta-analysis of individual data from 27 randomised trials.  The Lancet 2012; DOI:10.1016/S0140-6736(12)60367-5

Friday, June 8, 2012

Renin, angiotensin, aldosterone and you


There’s no escaping the kidneys in pharmacy.  Their significance in drug elimination, blood pressure and salt and fluid balance is undeniable.  

Renin is produced by juxtaglomerular cells in the afferent arteriole in response to decreased pressure in the kidney.  Renin is also responsible for the initial rate limiting step in the production of angiotensin.  Angiotensin-converting enzyme (ACE) facilitates the final step in the production of the active angiotensin II and is also responsible for the metabolism of certain peptides, such as bradykinin.

ACE-inhibitors (ACE-i) and angiotensin receptor blockers (ARB) reduce the effects of angiotensin II, which is responsible for vasoconstriction and aldosterone and sodium retention, to decrease the blood pressure and pressure within the kidney through different mechanisms.  ACE-i block ACE; however there are other pathways for the production of angiotensin leading to “ACE escape”.  ARBs would block angiotensin at its site of action, thereby bypassing the risk of “ACE escape”.  Both classes of medications can lead to increases in renin due to sustained lower pressures within the glomerulus.

Though increased bradykinin is the cause of the notorious ACE-i induced dry cough, it also provides added vasodilation.  A recent meta-analysis looking at mortality data from 20 trials utilizing an ACE-i or an ARB compared with a control showed that ACE-i offered a 10% mortality decrease compared with ARBs and the control drug or placebo.  The meta-analysis excluded patients who had heart disease or kidney disease, where RAAS inhibition has already been shown to have significant added benefits.  

The analysis shows that there is a clear mortality benefit to using an ACE-i in patients with hypertension without other comorbidities that would indicate RAAS inhibition.  If a patient is unable to take an ACE-i, there is no added mortality benefit to using an ARB over another antihypertensive.

Aliskiren, or Tekturna, is a direct renin inhibitor, the newest class of RAAS inhibitors.   Researchers hypothesized that using aliskiren in combination with an ACE-i or an ARB would improve outcomes by targeting RAAS through two mechanisms.  The “Aliskiren trial in type 2 diabetes using cardio-renal endpoints” studying aliskiren with an ACE-i or and ARB in diabetics was stopped early in December due to futility as well as increased risk of renal impairment, hypotension, and hypokalemia.  Prior to this in 2008, the TARGET study had also shown lack of benefit with combining an ACE-i and an ARB in patients with vascular disease or diabetes with organ damage.

The Food and Drug Administration, FDA, has recently placed a warning on aliskiren against its use in combination with an ACE-i or an ARB in patients with diabetes or moderate to severe renal impairment. 

While both an ACE-i or an ARB has clear benefit in patients with kidney disease or heart failure, ACE-i are superior to ARBs in mortality benefit in patients with hypertension alone.  Combining an ACE-i with an ARB or aliskiren should be avoided.

References:
Atlas SA.  The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.  Journal of Managed Care Pharmacy 2007; 13(8): S9-S20.

van Vark LC, Bertrand M, Akkerhuis KM et al.  Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients.  European Heart Journal 2012; DOI:10.1093/eurheartj/ehs075. Available at: http://eurheartj.oxfordjournals.org
Lowes R. No aliskiren with ACE inhibitors, ARBs in some patients: FDA.  theheart.org April 20, 2012.  Available at http://www.theheart.org/article/1388139.do